Trial Profile

Safety, Tolerability, Pharmacodynamics and Efficacy of HBM9161 Weekly Subcutaneous Administration in Patients With Neuromyelitis Optica Spectrum Disorders (NMOSD) in China

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 27 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Batoclimab (Primary) ; Methylprednisolone; Methylprednisolone; Prednisone
Indications Neuromyelitis optica
Focus Adverse reactions; Proof of concept
Sponsors Harbour BioMed

Most Recent Events

09 Jan 2022 Status changed from recruiting to completed.
15 Dec 2021 Planned End Date changed from 31 Dec 2021 to 31 Jan 2022.
15 Dec 2021 Planned primary completion date changed from 6 Dec 2021 to 24 Dec 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com